Sector News

Fujifilm makes yet another deal to jack up cell and gene therapy capacity

March 27, 2022
Life sciences

In 2018, Japanese multinational conglomerate Fujifilm up and decided it wanted to become a major player in supplying cell and gene therapy manufacturing, so it purchased two key companies—one in the U.S. and in the other in Japan—to jump-start its goal.

Four years later, the spending spree continues: Fujifilm has gobbled up Shenandoah Biotechnology for an undisclosed sum, again to increase its cell and gene therapy capabilities.

The Warminster, Pennsylvania-based Shenandoah boosts Fujifilm’s ability to produce recombinant proteins—especially growth factors and cytokines—used in manufacturing cell and gene therapies.

Shenandoah also comes with an upgraded cGMP facility with bio-command software, a new Tuttnauer autoclave sterilizer, a 16×16 ColdBox, and new air handling and RODI water systems, according to its website.

“Shenandoah Biotechnology’s portfolio of recombinant proteins complement our advanced cell culture solutions and expertise in bioprocessing, providing our collective customers a single point of access for their life science research, discovery, and cell and gene therapy needs,” Yutaka Yamaguchi, CEO of Fujifilm Irvine Scientific, said in a release.

Fujifilm said it welcomed “all members” of the Shenandoah team. The privately held company was established in 2006.

In 2018, Fujifilm dove headfirst into the cell and gene therapy supply business with its simultaneous acquisition of Irvine Scientific Sales of California and IS Japan for $800 million.

Then, in September of last year, Fujifilm completed construction of a 250,000-square-foot facility in Tilburg, Netherlands. The site produces dry powder media and liquid media along with other raw materials used in producing cell and gene therapies. It also gave Fujifilm Irvine Scientific a hub from which to serve its customers in Europe.

By Kevin Dunleavy


comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach